Gilead Extends Tender Offer Timeline for Planned Acquisition of Arcellx
Gilead Sciences, Inc. has announced an extension of its ongoing tender offer to acquire all outstanding shares of common stock of Arcellx, signaling continued progress in one of the more closely watched biopharmaceutical acquisition efforts of 2026. The revised timeline provides additional opportunity for shareholders to participate in the transaction while the company works toward satisfying the remaining conditions required for completion.
Under the terms of the offer, Arcellx shareholders are being offered a total consideration consisting of two components. The primary component is a cash payment of $115.00 per share, payable without interest and subject to any applicable withholding taxes. In addition, shareholders will receive one contractual contingent value right (CVR) for each share tendered. This CVR entitles holders to a potential additional cash payment of $5.00 per CVR, also without interest and subject to withholding taxes, contingent upon the achievement of specific commercial milestones.
The contingent payment is tied to the future performance of Arcellx’s lead product candidate, anitocabtagene autoleucel (commonly referred to as anito-cel). Specifically, the milestone requires that cumulative worldwide sales of anito-cel exceed $6.0 billion on or before December 31, 2029. If this threshold is met, CVR holders would receive the additional payment on March 31, 2030. This structure reflects a growing trend in biopharmaceutical transactions, where contingent payments are used to bridge valuation gaps and align incentives between acquiring companies and target shareholders.
Originally scheduled to expire shortly after midnight on April 2, 2026, the tender offer has now been extended and will remain open until 5:00 p.m. Eastern Time on April 24, 2026. The extension allows additional time for shareholders to evaluate the offer and tender their shares, as well as for the companies to continue progressing toward the completion of the transaction.
Gilead has indicated that it expects the acquisition to close during the second quarter of 2026, provided that all necessary conditions are met or waived. These conditions include the tender of a sufficient number of shares such that, when combined with shares already owned by Gilead, the company holds at least a majority of Arcellx’s outstanding shares. In addition, the transaction remains subject to regulatory approvals and other customary closing requirements typical of transactions of this scale and complexity.
As of March 31, 2026, preliminary data from Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, indicates that approximately 4,389,763 shares of Arcellx common stock had been validly tendered and not withdrawn. This figure represents roughly 7.5% of the total outstanding shares at that time. While this level of participation reflects initial shareholder engagement, it also underscores the importance of the extension in providing additional time to reach the required majority threshold.
Importantly, shareholders who have already tendered their shares are not required to take any further action as a result of the extension. Their previously submitted tenders remain valid and will continue to be counted toward the overall total unless they choose to withdraw their shares in accordance with the terms of the offer.
The acquisition of Arcellx aligns with Gilead’s broader strategic focus on expanding its oncology portfolio, particularly in the area of cell therapies. Arcellx is known for its innovative approach to engineered cell therapies, including its work on next-generation CAR-T treatments designed to improve efficacy and safety profiles. The company’s lead program, anito-cel, has generated significant interest within the oncology community due to its potential in treating hematologic malignancies.
By pursuing this acquisition, Gilead aims to strengthen its position in the rapidly evolving field of cancer immunotherapy, building on its existing capabilities and pipeline. The inclusion of a CVR tied to anito-cel’s commercial success reflects confidence in the therapy’s long-term potential while also managing risk in a highly competitive and dynamic market.
The extension of the tender offer may also provide an opportunity for further engagement with shareholders, analysts, and other stakeholders as they assess the value proposition of the deal. Factors influencing shareholder decisions may include the upfront cash premium, the potential upside associated with the CVR, and broader market conditions affecting biotechnology valuations.
For shareholders seeking additional information or assistance with the tender process, Gilead has designated Innisfree M&A Incorporated as the information agent for the transaction. The firm is available to address questions and provide guidance regarding the mechanics of tendering shares, ensuring that investors have access to the resources needed to make informed decisions.
Overall, the extension of the tender offer represents a routine but important step in the acquisition process, allowing additional time to secure the necessary level of shareholder participation and complete regulatory requirements. As the revised deadline approaches, market participants will be closely monitoring tender levels and any further developments related to the transaction.
In conclusion, Gilead Sciences’ decision to extend its tender offer for Arcellx reflects both the complexity and strategic importance of the deal. With a compelling combination of upfront cash consideration and performance-based upside, the offer seeks to balance immediate value with future potential. As the companies move closer to a potential closing in the second quarter of 2026, the outcome of the tender process will play a निर्ण role in determining the next phase of this significant biopharmaceutical acquisition.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
Source Link:https://www.businesswire.com/
